Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exploring hydrophilic 2,2-di(indol-3-yl)ethanamine derivatives against Leishmania infantum.
Centanni A, Diotallevi A, Buffi G, Olivieri D, Santarém N, Lehtinen A, Yli-Kauhaluoma J, Cordeiro-da-Silva A, Kiuru P, Lucarini S, Galluzzi L. Centanni A, et al. Among authors: lehtinen a. PLoS One. 2024 Jun 13;19(6):e0301901. doi: 10.1371/journal.pone.0301901. eCollection 2024. PLoS One. 2024. PMID: 38870204 Free PMC article.
Expanding the Paradigm of Structure-Based Drug Design: Molecular Dynamics Simulations Support the Development of New Pyridine-Based Protein Kinase C-Targeted Agonists.
Lautala S, Provenzani R, Tarvainen I, Sirna K, Karhu ST, Grazhdankin E, Lehtinen AK, Sa'd H, Koivuniemi A, Xhaard H, Tuominen RK, Talman V, Bunker A, Yli-Kauhaluoma J. Lautala S, et al. Among authors: lehtinen ak. J Med Chem. 2023 Apr 13;66(7):4588-4602. doi: 10.1021/acs.jmedchem.2c01448. Epub 2023 Apr 3. J Med Chem. 2023. PMID: 37010933 Free PMC article.
Design of an international, phase IV, open-label study of simoctocog alfa in women/girls with hemophilia A undergoing surgery (NuDIMENSION).
Marquardt N, Langer F, Holstein K, Álvarez Román MT, Núñez Vázquez R, Miljić P, Drillaud N, Ardillon L, Lehtinen AE, Santoro RC, Napolitano M, Siragusa S, Gidley G, Jansen M, Knaub S, Oldenburg J. Marquardt N, et al. Among authors: lehtinen ae. Ther Adv Hematol. 2024 Dec 1;15:20406207241300040. doi: 10.1177/20406207241300040. eCollection 2024. Ther Adv Hematol. 2024. PMID: 39624518 Free PMC article.
Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS).
Fischer K, Lassila R, Peyvandi F, Gatt A, Gouw SC, Hollingsworth R, Lambert T, Kaczmarek R, Carbonero D, Makris M; European HAemophilia Safety Surveillance (EUHASS) participants. Fischer K, et al. Res Pract Thromb Haemost. 2024 May 27;8(4):102461. doi: 10.1016/j.rpth.2024.102461. eCollection 2024 May. Res Pract Thromb Haemost. 2024. PMID: 39026659 Free PMC article.
Development of a Coagulation Disorders Unit.
Szanto T, Helin T, Joutsi-Korhonen L, Lehtinen AE, El Beayni N, Lepäntalo A, Lassila R. Szanto T, et al. Among authors: lehtinen ae. Semin Thromb Hemost. 2024 Jul;50(5):687-694. doi: 10.1055/s-0044-1779633. Epub 2024 Feb 19. Semin Thromb Hemost. 2024. PMID: 38373723 Review.
Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context.
Astermark J, Baghaei F, Strandberg K, Toplican PG, Birkedal MF, Grahn EE, Hansson C, Kampmann P, Lehtinen AE, Täckström K, Holme PA, Magnusson M. Astermark J, et al. Among authors: lehtinen ae. Ther Adv Hematol. 2023 Oct 17;14:20406207231202306. doi: 10.1177/20406207231202306. eCollection 2023. Ther Adv Hematol. 2023. PMID: 37859645 Free PMC article.
94 results